Background: The incidence of Crohn's disease (CD) is rising, and still many patients have to undergo repeated surgery due to failure of pharmacologic therapy.
Results: While the introduction of anti-TNF agents started biologic therapy for CD and revolutionized the management of patients, the number of patients who do not respond to this treatment or lose their initial response to this treatment is still substantial. Therefore, the recent introduction of new therapeutic options with anti-integrins and new anti-cytokines was an important step to provide more effective treatment for our patients. Yet, next to new drugs also new treatment strategies have been proposed.
Conclusion: In this article, we will review these new aspects of pharmacologic therapy for CD -patients.
Keywords: Anti-TNF; Anti-cytokine; Anti-integrin; Crohn's disease; Targeted therapy.
Copyright © 2019 by S. Karger AG, Basel.
Conflict of interest statement
The author of this publication received a honorarium and was a speaker for Takeda. The terms of this arrangement have been reviewed and approved by Klinikum rechts der Isar, Technische Universität München.
[Anti-TNF Therapy in Treatment of Luminal Crohn's Disease]B Marko et al. Acta Med Croatica 67 (2), 179-89. PMID 24471301. - ReviewBiologic drugs directed against main proinflammatory mediator in inflammatory bowel disease (IBD)--tumor necrosis factor alpha (TNFalpha)--represent very effective and cl …
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services UtilizationME Kuenzig et al. J Can Assoc Gastroenterol 2 (Suppl 1), S17-S33. PMID 31294382.1. Forecasting models are necessary to predict the rising costs attributable to biologics associated with increasing prevalence of IBD, more frequent use of these medicat …
Integrin Antagonists as Potential Therapeutic Options for the Treatment of Crohn's DiseaseLP McLean et al. Expert Opin Investig Drugs 25 (3), 263-73. PMID 26822204. - ReviewAnti-integrins are effective for the treatment of Crohn's disease, even in patients refractory to other therapies. Their use should be considered in patients with Crohn's …
Transcending Conventional Therapies: The Role of Biologic and Other Novel TherapiesWJ Sandborn. Inflamm Bowel Dis 7 Suppl 1, S9-16. PMID 11380043. - ReviewBiologic and other novel therapies targeted to specific pathogenic processes offer the potential for improved treatment outcomes in patients with Crohn's disease and alte …
Crohn's Targeted Therapy: Myth or Real Goal?KJ Schmidt et al. Curr Drug Discov Technol 6 (4), 290-8. PMID 20025597.The broad spectrum of chronic inflammatory bowel diseases encompasses the two main entities Crohn's disease (CD) and ulcerative colitis (UC). Rapid action and long-term d …